Proactive Investors - Run By Investors For Investors

Renovo ends Prevascar development

Renovo ends Prevascar development

Renovo (LON:RNVO) today confirmed that it will now perform any further work on Prevascar following the completion of a clinical trial.

The company says that it will continue to focus on its merger and acquisition plans and its share buy-back programme as a way to enhance shareholder value.

The clinical trial results follow the disappointing results of the Juvista trial in February 2011. Subsequently, Renovo’s remaining trials which had already been contracted had continued.

Today, Renovo reported that 56 patients were enrolled in the trial of the Prevascar scar treatment. It said there was a ‘small but significant’ reduction in scar width compared to placebo after one month, however by month 12 there was in fact a ‘small but significant’ improvement in the placebo scar width compared to Prevascar. 

Meanwhile, most other assessments showed no difference between treatments. 

In November, Renove told investors that it was considering all options to maximise value including acquisitions and mergers of external companies.


Register here to be notified of future RNVO Company articles
View full RNVO profile

Renovo Group Plc Timeline

December 13 2012
December 15 2011
November 18 2011

Related Articles

July 31 2015
If UniBio’s plans come to fruition it won’t be too long before the company orchestrates a major adjustment to the food-chain.
June 02 2015
Redx Pharma has unveiled a potential breakthrough in the fight against antibiotic resistant infections.
February 19 2015

Ergomed has agreed to co-develop a drug in a deal that will see it receive a stake in its partner, Sweden’s Dilaforette.

© Proactive Investors 2015

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.